Drug Eluting Stent (DES) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Drug Eluting Stent Market

The Drug Eluting Stent Market size was valued at USD 5.71 billion in 2023, and the market is now projected tgrow t13.52 USD billion by 2032, exhibiting a CAGR of 6.3% during the forecast period of 2023-2030.

The pandemic has been anticipated tbe a bane for the entire industrial developments of various market and fields. This has affected the overall supply and demand chains of the particular market. As a result of the government's lockdown and other steps tstop the coronavirus from spreading, all supply activities were postponed, which decreased the amount of product related tthis domain. These factors affected the Drug Eluting Stent Market growth.

This is the major factor attributing the growth of this particular market. This factor is majorly involved in taking the revenue numbers above the skies and soaring greater heights and alsthe sales and demands have been proliferation and increased its value tgreater extent. It is anticipated that the growing incidence of coronary artery disorders and the rising cost of healthcare in emerging nations would increase demand for these stents on the international market. Additionally, the market for drug eluting stents is expected trise due tthe increasing prevalence of peripheral arterial disease (PAD). Effective cardiovascular intervention research and development, as well as the launch of DES based on bioresorbable polymers, are anticipated tbe crucial tmanufacturers' strategic growth in the DES market. During the projection period, the introduction of technologically sophisticated stents is expected tbe one of the key drivers driving market growth. These particular growth driving factors have been recorded tattribute the Drug Eluting Stent Market Share.

It is necessary for a product market twalk with the trends in order tincreases its lucracy and profits in shares and all over revenue. In the treatment of cardiovascular illnesses, new avenues for percutaneous coronary procedures have been made possible by the development of drug-eluting stents. The creation and application of totally bioresorbable polymers seeks tprevent restenosis, guarantee patient safety, and enhance treatment clinical results. Numerous market participants have introduced sophisticated stents made of bioabsorbable polymers while concentrating on research and development. The DES guarantees that there is little tissue injury and speeds up the vessels' ability trecover. This is most likely the result of reorganizing dynamic and sustainable systems that support human residents' health and well-being.

Comprehensive Analysis of Drug Eluting Stent Market

The segmentation of this particular market has been divided and then further subdivided intvarious categories. The market is divided intperipheral stenting and coronary stenting based on indication. Of the stenting segments, the coronary stenting section was the most prominent. Sirolimus, Paclitaxel, Zotarolimus, Everolimus, and Others are the drug categories intwhich the market is divided. Because sirolimus is highly preferred by end users, the category is predicted trise at a large CAGR during the projection period. The market is separated intcobalt-chromium, platinum-chromium, nitional, and other segments based on scaffold. Throughout the forecast period, the cobalt-chromium segment is expected tdominate the market. Some of the main causes of the hospitals segment's dominance include growing healthcare costs and the construction of new hospitals in developing nations.

North America holds the largest market over the forecast period, according tthe conclusions based on our research methodology. North America's favorable reimbursement policies and the region's expanding cardiovascular disease prevalence are projected tcontribute tits significant market share. In addition, some of the key reasons driving the market's expansion in North America are the growing need for drug-eluting scaffolds made of biodegradable polymers and the increase in research and development efforts for vascular stents. The region is expected tmaintain a significant proportion during the projected period.

Global markets are fiercely competitive and highly fragmented. Due ttheir creative packaging solutions, a few group of large market companies hold a fair amount of market share. Some of the major Companies includes Boston Scientific Corporation (U.S.), Abbott (U.S.), Medtronic (Ireland), Biotronik (Germany), TerumCorporation (Japan), MicroPort Scientific Corporation (China), and Sahajanand Medical Technologies (India)..

In June 2021, This particular company has attributed the market growth in terms of revenue and shares system. Abbott reported that their XIENCE stents, the shortest blood thinning course for patients with high bleeding risk in the U.S., have been approved by the U.S. FDA for one-month Dual Antiplatelet Therapy (DAPT) and granted CE Mark approval in Europe.

Segmentation Table

ATTRIBUTE DETAILS

Study Period - 2015-2026

Base Year - 2018

Forecast Period - 2019-2026

Historical Period - 2015-2017

Unit - Value (USD billion)

Segmentation By Type

• Coronary Stenting
• Peripheral Stenting

By Scaffold

• Cobalt-Chromium
• Platinum-Chromium
• Nitinol
• Others

By Drug

• Sirolimus
• Paclitaxel
• Zotarolimus
• Everolimus
• Others

By End User

• Hospitals
• Specialty Clinics

By Geography

• North America (the U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.